TL;DR
This paper reports on the first-in-human clinical trial of 23ME-00610, a novel antibody targeting the CD200R1 immune checkpoint. The study found that 23ME-00610 is safe and well-tolerated, with pharmacokinetic and pharmacodynamic profiles supporting a dosing regimen of 1,400 mg every three weeks. Preliminary evidence of clinical benefit, particularly in patients with high CD200 expression on their tumors, suggests this antibody holds promise for treating advanced solid malignancies.
What Problem Does This Paper Address?
The field of cancer immunotherapy has seen remarkable success with checkpoint inhibitors that unleash the immune system against tumors. However, a significant portion of patients do not respond to existing therapies, highlighting the need for new targets and strategies to overcome immune evasion. CD200R1 is an inhibitory immune checkpoint receptor that plays a role in immune tolerance. Its ligand, CD200, is often overexpressed on tumor cells, creating an immunosuppressive microenvironment. By blocking the CD200-CD200R1 interaction, 23ME-00610 aims to restore anti-tumor immune responses. This study addresses the critical question of whether this novel approach is safe and effective in humans with advanced solid tumors.
Methods
This was an open-label, Phase 1, dose-escalation study of 23ME-00610 in participants with advanced solid malignancies. The study employed an accelerated titration design for the lowest dose levels, followed by a traditional 3+3 design for dose escalation. Key assessments included:
- Safety and Tolerability: Monitored through vital signs, physical examinations, laboratory tests, and adverse event (AE) reporting using NCI-Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
- Pharmacokinetics (PK): Serum concentrations of 23ME-00610 were measured using a validated ligand-binding assay to determine parameters like Cmax, AUC, and half-life.
- Pharmacodynamics (PD): Evaluated target engagement through assays measuring CD200R1 receptor occupancy (RO) on immune cells (CD4+ T cells and neutrophils) and levels of free and total soluble CD200R1 in the blood.
- Exploratory Biomarkers: Immunohistochemistry (IHC) was used to assess CD200 and CD200R1 expression in tumor tissue. Additionally, participants underwent germline genetic analysis and polygenic risk score (PRS) calculation to explore potential correlations with safety and efficacy.
- Efficacy: Tumor response was assessed using RECIST v1.1 and iRECIST criteria.
Datasets
The study utilized data from 28 participants enrolled in the Phase 1 trial. These participants provided blood and, where available, archival tumor tissue samples. Germline genetic data was collected via saliva samples and analyzed using the 23andMe genotyping platform. The study also referenced data from the 23andMe, Inc. Research Cohort for PRS calculations. No new benchmarks were introduced; standard clinical trial assessment tools and assays were employed.
Key Insights and Ideas
- CD200R1 as a Validated Target: The study builds upon prior genetic research (GWAS on the 23andMe database) that identified CD200R1 as a promising target for cancer therapy, suggesting a genetic basis for its therapeutic potential.
- Dose-Dependent Target Saturation: The PK/PD data clearly demonstrated that doses of 60 mg and above were required to achieve sustained saturation of CD200R1 on peripheral immune cells and to effectively block soluble CD200R1. Lower doses did not achieve this level of target engagement.
- Predictive Biomarker Potential: Preliminary analysis suggested a trend where higher CD200 expression on tumor cells might correlate with a better clinical response to 23ME-00610, hinting at CD200 expression as a potential predictive biomarker.
- Immune-Related AEs (irAEs) as a Sign of Activity: The occurrence of irAEs, particularly at doses ≥60 mg, was consistent with the drug's mechanism of action and was observed more frequently in patients who experienced clinical benefit, aligning with observations from other immune checkpoint inhibitors.
- Feasibility of Real-Time Genetic Analysis: The study successfully implemented prospective germline genetic analysis and PRS calculation, demonstrating the feasibility of integrating such data into early-phase clinical trials for biomarker discovery.
Key Results
- Safety and Tolerability: 23ME-00610 was generally safe and well-tolerated. No treatment-related deaths or grade 4/5 adverse events were observed. The maximum tolerated dose (MTD) was not reached.
- PK Profile: 23ME-00610 exhibited linear and dose-proportional pharmacokinetics for doses ≥60 mg, with a median terminal half-life of approximately 13 days at 1,400 mg.
- PD Profile: Peripheral saturation of CD200R1 was achieved at doses ≥60 mg. Soluble CD200R1 levels were suppressed, and total soluble CD200R1 increased with dosing.
- Efficacy: One confirmed partial response (PR) was observed in a patient with well-differentiated pancreatic neuroendocrine cancer. Thirteen participants (46.4%) achieved stable disease (SD).
- Recommended Phase 2 Dose: Based on safety, tolerability, PK/PD, and preliminary clinical activity, 1,400 mg every three weeks (Q3W) was selected as the recommended dose for further study.
Limitations and Future Work
- Small Sample Size: As a Phase 1 study, the sample size (N=28) is small, limiting the statistical power for definitive conclusions on efficacy and biomarker correlations.
- Exploratory Biomarker Analysis: The correlations between CD200 expression and clinical benefit, as well as the analysis of germline genetic data, were exploratory and require further validation in larger patient cohorts.
- Limited Tumor Penetration: While peripheral target engagement was demonstrated, the authors suggest that higher doses may be needed to ensure sufficient CD200R1 saturation within the tumor microenvironment, given potential variability in drug penetration and target expression.
- Future Work: The paper highlights the need for further investigation in Phase 2a expansion cohorts, including those with ovarian cancers and neuroendocrine neoplasms, to further optimize dosing and explore the predictive value of CD200 tumor expression. Continued research into the role of germline genetics in predicting irAEs and treatment outcomes is also suggested.
Summary updated